Boehringer Ingelheim to show final Phase IIb data for it's BI 20133 protease inhibitor...

New data from the Boehringer Ingelheim hepatitis C virus (HCV) portfolio will be presented in oral scientific sessions at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place 30 March-3 April in Berlin, Germany. The data will include final results from SILEN-C1 and SILEN-C2, two Phase IIb studies evaluating one of Boehringer Ingelheim’s investigational compounds for Hepatitis C treatment, the once-daily, oral protease online pharmacy viagra BI 201335 in combination with the current standard-of-care (pegylated-interferon and ribavirin).



Oral presentations (Friday, 1 April, 2011; Parallel Session: HCV Drug Development, Hall 1)



SILEN-C1: Sustained Virologic Response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naïve patients with chronic genotype 1 HCV infection

(Abstract 60. M. Sulkowski, et al. 16:00h - 16:15h)



SILEN-C2: Sustained Virologic Response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R

(Abstract 66. M. Sulkowski, et al. 17:30h - 17:45h)



Boehringer Ingelheim is continuing its long heritage in virology and is dedicated to developing new medicines to improve treatment for HCV patients. BI 201335 is part of a growing HCV portfolio that is being investigated with the aim of identifying a simpler HCV cure, overcoming the challenges of current treatments.



Additional HCV studies to be presented at EASL



SVR and Pharmacokinetics of the HCV protease inhibitor BI201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV

(Poster 1231. S. Pol, et al.; Saturday, 2 April, 2011, 09:00h - 18:00h)



Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335 (Poster 1236. R. Sane, et al.;Saturday, 2 April, 2011, 09:00h - 18:00h)

BI201335 Pharmacokinetics and early effect on viral load in HCV genotype-1 patients

(Poster 1249. C. Yong, et al.;Saturday, April 2, 2011, 09:00h - 18:00h)



Preclinical Characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BILB 1941 (Poster 1215. G. Kukolj et. al.; Friday, 30 March, 2011, 09:00h - 18:00h)

The abstracts can be accessed through the EASL website, www.easl.eu.



For more information on BI’s hepatitis portfolio, please visit www.boehringer-ingelheim.com and follow us on Twitter. www.twitter.com/boehringer.



Boehringer Ingelheim



The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.



Within the company’s global research network, Virology is one of the seven R&D areas with focus on Hepatitis C.



In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro (US $17.7 billion) while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

MeO Summer Pill

MÄ“O is the next evolution of designer cheap cialis after BZP. MeO is the only designer pill that comes on like the real thing and gives you a brighter altered drug experience for 3 - 4 hours of ecstatic body feeling and relaxed summer mindset, then tapers off and puts you back to normal. No residual effect, no hangover. You can even go to sleep on it! Stargate identified that many of the unwanted side effects from party cheap cialis were from the placement of one carbon atom. Shifting that one atom to a more optimal position produced an entirely new product called MÄ“O. MÄ“O is a relaxing social chill out. It melts away the stress and anxiety of 2007 and allows you to truly chill out this holiday season. Perfect for NZ's hot summer days or the UK's Winter New Years nights. MÄ“O does not produce the complaints of anxiety or insomnia, just relaxed chilled out people - the feeling of a good pill coming on - and a few hours later it has that nice clean exit. You can go to sleep after MÄ“O. You have got to try this one. Brand new from Stargate. Each packet contains 2 tablets = 2 doses.


Perfect for lazy summer moments outside chating with friends. Vastly different to the old BZP pills, MeO has been refined at a molecular level, resulting in a smoother yummier body buzz and a chattier vibe.
We don't hear about insomnia, anxiety or hangovers from MeO, just the relaxing calming body feeling of a good pill coming on.

Contains 2 Tablets (2doses)

Recommended dose 1 tablet

Each tablet contains 200mg MeO (Methoxyphenylpiperazine)

Take one tab. lasts 2-4 hours. Try to wait a few weeks between experiences.

It is dangerous to exceed stated dose. In general if you probably just take one pill, you won't experience insomnia, nausea or hangover symptoms. Drink water not alcohol and don't take other drugs.

Thanks to SparkPlug for this.

Side Effects

See also: cheap cialis | cheap cialis | 

Side effects - Viagra's include sudden loss of vision & hearing. Aren't those the same as a really good orgasm?